MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.
The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...
As the U.S. IPO market opens back up, here's how biotech CEO Marc de Garidel says business leaders can capitalize.
GlobalData on MSN
MapLight’s $251m IPO sees schizophrenia drug developers on top
Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...
The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...
(Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company ...
A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...
Stockhead on MSN
The healthcare IPO drought is about to break as the sector ‘significantly outperforms’, says the ASX
A senior ASX executive says the drought of life sciences IPOs is poised to become a deluge as investors embrace the hitherto unloved sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback